Efficient CRISPR-Cas13d-Based Antiviral Strategy to Combat SARS-CoV-2

Area of Science:

• Molecular Biology
• Virology
• Gene Editing

Background:

• The SARS-CoV-2 pandemic highlights the need for adaptable antiviral strategies due to emerging variants.
• CRISPR-based gene editing offers a promising therapeutic approach due to its programmable nature.

Purpose of the Study:

• To investigate the efficacy of the RNA-targeting CRISPR-Cas13d system against conserved sequences in the SARS-CoV-2 genome.
• To assess the potential of this system for combating current SARS-CoV-2 infections and future coronavirus zoonotic outbreaks.

Main Methods:

• Design of 29 CRISPR-RNAs (crRNAs) targeting highly conserved regions of the SARS-CoV-2 genome.
• Evaluation of crRNA efficiency in silencing reporter genes and inhibiting SARS-CoV-2 replicons.
• Testing the cross-reactivity of effective crRNAs against SARS-CoV.

Main Results:

• Several designed crRNAs demonstrated effective silencing of viral RNA targets and inhibition of SARS-CoV-2 replication.
• The crRNAs effective against SARS-CoV-2 also showed activity against SARS-CoV, indicating broad applicability.
• Antiviral activity was observed only with crRNAs targeting the plus-genomic RNA strand, not the minus-genomic RNA.

Conclusions:

• The CRISPR-Cas13d system is a viable strategy for targeting conserved viral RNA sequences, adaptable to new variants and future outbreaks.
• The differential activity against plus- and minus-genomic RNA strands provides crucial insights into viral RNA biology and antiviral design.
• This approach holds potential for developing next-generation antivirals against coronaviruses.